(TRIANGLE) Autologous Transplantation after a Rituximab/Ibrutinib/Ara-c containing iNduction in Generalized mantle cell Lymphoma - a randomized European MCL network trial

Project summary

The mantle cell lymphoma is a form of non-Hodgkin’s lymph node cancer. The standard treatment for mantle cell lymphoma consists of 2 parts: first an induction treatment to reduce the disease as much as possible, then a consolidation treatment to maintain the achieved effect. The induction treatment consists of alternating R-CHOP and R-DHAP. These are combinations of the drug rituximab (immunotherapy with antibodies) and chemotherapy (CHOP1 or DHAP2). BEAM3 (high-dose chemotherapy) is given during the consolidation phase, followed by a stem cell transplant. Despite this treatment, patients with mantle cell lymphoma are difficult to cure, especially when the disease returns.
Ibrutinib is a new drug that can kill the mantle lymphoma cells. This project will investigate whether  ibrutinib improves the chances of survival for patients with mantle cell lymphoma when used in the induction and/or consolidation phase and whether it makes stem cell transplant superfluous.

This research hopes to improve the survival of patients with mantle cell lymphoma by adding a new drug (ibrutinib) to current treatment.